JPWO2021228978A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021228978A5 JPWO2021228978A5 JP2022554243A JP2022554243A JPWO2021228978A5 JP WO2021228978 A5 JPWO2021228978 A5 JP WO2021228978A5 JP 2022554243 A JP2022554243 A JP 2022554243A JP 2022554243 A JP2022554243 A JP 2022554243A JP WO2021228978 A5 JPWO2021228978 A5 JP WO2021228978A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- ctla
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 37
- 239000000427 antigen Substances 0.000 claims 36
- 102000036639 antigens Human genes 0.000 claims 36
- 108091007433 antigens Proteins 0.000 claims 36
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 6
- 229950007217 tremelimumab Drugs 0.000 claims 5
- 230000010109 chemoembolization Effects 0.000 claims 3
- 229950009791 durvalumab Drugs 0.000 claims 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023191381A JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023554P | 2020-05-12 | 2020-05-12 | |
| US63/023,554 | 2020-05-12 | ||
| PCT/EP2021/062695 WO2021228978A1 (en) | 2020-05-12 | 2021-05-12 | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191381A Division JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524359A JP2023524359A (ja) | 2023-06-12 |
| JPWO2021228978A5 true JPWO2021228978A5 (es) | 2023-06-26 |
| JP7387912B2 JP7387912B2 (ja) | 2023-11-28 |
Family
ID=75977756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Active JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
| JP2023191381A Pending JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191381A Pending JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210355224A1 (es) |
| EP (1) | EP4021940A1 (es) |
| JP (2) | JP7387912B2 (es) |
| KR (1) | KR20230009354A (es) |
| CN (1) | CN114729054A (es) |
| AU (2) | AU2021269832A1 (es) |
| BR (1) | BR112022021893A2 (es) |
| CA (1) | CA3158607A1 (es) |
| IL (2) | IL297640A (es) |
| MX (1) | MX2022006728A (es) |
| TW (1) | TW202207976A (es) |
| WO (1) | WO2021228978A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024054897A1 (en) * | 2022-09-07 | 2024-03-14 | The University Of Chicago | Methods for treating cancer with hyperactive adar enzymes |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| KR20050011741A (ko) | 2002-04-11 | 2005-01-29 | 메드이뮨 백신즈 인코포레이티드 | 분무 건조에 의한 생물학적 활성 물질의 보존 |
| WO2003086443A1 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| CA2482448C (en) | 2002-04-11 | 2014-07-08 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| US7923029B2 (en) | 2002-04-11 | 2011-04-12 | Medimmune Llc | Spray freeze dry of compositions for pulmonary administration |
| JP4680601B2 (ja) | 2002-12-17 | 2011-05-11 | メディミューン・エルエルシー | 生物活性材料の高圧噴霧乾燥 |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| CR20170143A (es) * | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| EP3277318A1 (en) * | 2015-04-01 | 2018-02-07 | Medimmune Limited | Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| WO2017220569A1 (en) * | 2016-06-20 | 2017-12-28 | F-Star Delta Limited | Binding molecules binding pd-l1 and lag-3 |
| EP3519827A1 (en) * | 2016-09-27 | 2019-08-07 | Oncologie, Inc. | Methods for treating cancer with bavituximab based on levels of 2-glycoprotein 1, and assays therefor |
| JP2020522486A (ja) * | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| CN112543809A (zh) * | 2018-06-15 | 2021-03-23 | 米纳治疗有限公司 | 包含C/EBPα saRNA的组合疗法 |
-
2021
- 2021-05-12 US US17/318,017 patent/US20210355224A1/en active Pending
- 2021-05-12 TW TW110117153A patent/TW202207976A/zh unknown
- 2021-05-12 JP JP2022554243A patent/JP7387912B2/ja active Active
- 2021-05-12 AU AU2021269832A patent/AU2021269832A1/en active Pending
- 2021-05-12 IL IL297640A patent/IL297640A/en unknown
- 2021-05-12 BR BR112022021893A patent/BR112022021893A2/pt unknown
- 2021-05-12 CA CA3158607A patent/CA3158607A1/en active Pending
- 2021-05-12 EP EP21726376.3A patent/EP4021940A1/en active Pending
- 2021-05-12 CN CN202180006543.2A patent/CN114729054A/zh active Pending
- 2021-05-12 KR KR1020227024530A patent/KR20230009354A/ko active Search and Examination
- 2021-05-12 IL IL311936A patent/IL311936A/en unknown
- 2021-05-12 WO PCT/EP2021/062695 patent/WO2021228978A1/en unknown
- 2021-05-12 US US17/765,585 patent/US20220363762A1/en active Pending
- 2021-05-12 MX MX2022006728A patent/MX2022006728A/es unknown
-
2023
- 2023-11-09 JP JP2023191381A patent/JP2024016209A/ja active Pending
-
2024
- 2024-05-03 AU AU2024202963A patent/AU2024202963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519295A5 (es) | ||
| JP2020521778A5 (es) | ||
| JP2017031160A5 (es) | ||
| JP2009519257A5 (es) | ||
| JP2007515469A5 (es) | ||
| JP2017507652A5 (es) | ||
| JP2011507932A5 (es) | ||
| JP2016530323A5 (es) | ||
| JP2017501167A5 (es) | ||
| JP2006522830A5 (es) | ||
| JP2013533858A5 (es) | ||
| JP2015534578A5 (es) | ||
| JP2015532292A5 (es) | ||
| JP2013520442A5 (es) | ||
| JP2009525764A5 (es) | ||
| JP2010531140A5 (es) | ||
| JP2010535713A5 (es) | ||
| RU2010145177A (ru) | Лекарственное средство для лечения рака печени | |
| JP2012102122A5 (es) | ||
| JP2010500370A5 (es) | ||
| JP2016520520A5 (es) | ||
| JP2010515774A5 (es) | ||
| JP2024016209A5 (es) | ||
| WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| JP2020506728A5 (es) |